Alvotech and Teva Pharmaceuticals have announced approval from the US Food and Drug Administration (FDA) for Selarsdi (ustekinumab-aekn) via subcutaneous injection.
Riding high on Teva’s success under its recent “Pivot to Growth” strategy, chief executive Richard Francis—in his first year at the helm of the generics and innovative medicines hybrid—has emerged as one of the industry’s top-paid CEOs for 2023.
A new global licensing agreement is set to advance development of an oncology biosimilar candidate. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. and Spain-based biopharmaceutical company mAbxience, have entered into a strategic deal for a drug candidate that is in development for treating multiple indications in the oncology space.
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
April 10 (Reuters) - Pfizer (PFE.N), opens new tab subsidiary Wyeth has agreed to pay $39 million to resolve claims from drug purchasers that it conspired with rival Teva to delay launching a less-expensive version of the antidepressant drug Effexor XR.
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
As Teva advances its Pivot to Growth strategy under CEO Richard Francis, the company is making good on its pledge to beef up its biosimilar pipeline through outside deals.
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
Enforcement Report - Week of April 3, 2024